Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amgen Inc. (AMGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer and a component of the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen uses SEC filings to report financial results, material events and other information relevant to shareholders.
Amgen’s Form 8-K filings illustrate how the company communicates quarterly performance. For example, 8-K reports dated August 5, 2025 and November 4, 2025 describe second and third quarter earnings press releases, including unaudited results of operations and financial position. These filings also explain Amgen’s use of non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and Free Cash Flow. The company outlines which acquisition-related expenses, restructuring charges and other items are excluded from GAAP results and how the related tax effects are calculated.
On this page, users can review Amgen’s current and historical SEC documents, including Forms 10-K and 10-Q when available, 8-Ks for earnings and other material events, and additional filings that may address debt offerings, governance matters or other disclosures. Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly understand topics such as segment performance, non-GAAP adjustments, liquidity metrics and risk factor discussions without reading every page.
The filings page also surfaces information relevant to questions about AMGN stock, such as how management describes its financial performance, what non-GAAP metrics it emphasizes and how it discusses acquisition-related charges and restructuring initiatives. Real-time updates from EDGAR, combined with AI-generated overviews, allow investors to follow new Amgen filings as they appear and to place each document in the context of the company’s broader financial and regulatory history.
Amgen Inc. has filed an automatic shelf registration to issue a wide range of securities over time and to register potential resale of common stock by selling securityholders. The filing covers debt securities, common and preferred stock, warrants, rights, securities purchase contracts and units, and depositary shares.
Amgen may conduct offerings from time to time using prospectus supplements that will set specific terms such as amounts, prices and methods of sale. The company plans to use any primary offering proceeds for general corporate purposes, while it will not receive proceeds from common stock sold by selling securityholders.
Amgen Inc. reports a large, diversified biotechnology business focused on human therapeutics, with 2025 product sales of
The company’s portfolio spans osteoporosis (Prolia, EVENITY), cardiovascular disease (Repatha), inflammation and immunology (ENBREL, Otezla, TEZSPIRE), oncology and hematology (BLINCYTO, KYPROLIS, Vectibix, IMDELLTRA/IMDYLLTRA), rare diseases (TEPEZZA, KRYSTEXXA, TAVNEOS, UPLIZNA) and multiple biosimilars. Key 2025–2026 regulatory events include broader U.S. Repatha labeling, multiple new UPLIZNA indications, full approval of IMDELLTRA in extensive-stage small cell lung cancer, new TEZSPIRE indications, and EU approval of TEPEZZA.
Amgen highlights an extensive pipeline, led by obesity and cardiometabolic candidate MariTide in multiple Phase 3 programs and positive long-term Phase 2 data, as well as cardiovascular RNA agent olpasiran and several biosimilar antibodies in late-stage development. The company also faces rising biosimilar and generic competition, loss of key patents such as RANKL antibodies for Prolia/XGEVA, and U.S. pricing pressure from the Inflation Reduction Act, including mandated Medicare price cuts for ENBREL from
Amgen Inc. executive James E. Bradner, EVP, Research and Development, reported two dispositions of Amgen common stock in transactions coded F on February 9, 2026. The Form 4 shows 2,151 shares and 953 shares disposed of at $384.32 per share in separate entries.
After these transactions, the reported directly owned balances were 28,331 shares and 27,378 shares in the respective lines. The holdings include 1,205 dividend equivalents granted under Amgen’s 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis as related RSUs vest.
Amgen Inc. furnished an 8-K to share that it has issued a press release with unaudited results for the fourth quarter and full year ended December 31, 2025, along with its financial position as of that date. The press release includes several non-GAAP measures such as non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses, including non-GAAP cost of sales, R&D, and selling, general and administrative expenses, each reconciled to the nearest GAAP figure. Amgen also presents Free Cash Flow, defined as GAAP operating cash flow minus capital expenditures, and EBITDA and a debt leverage ratio based on GAAP total debt and EBITDA. The company explains it uses these metrics internally for planning, performance evaluation, and incentive compensation and believes they help investors assess ongoing operations and liquidity. The non-GAAP information is described as supplemental to, and not a replacement for, GAAP results and is furnished, not filed, under the Exchange Act.
Amgen Inc. filed an 8-K stating it signed a Termination Agreement with Kyowa Kirin Co., Ltd. to end their License and Collaboration Agreement dated June 1, 2021. The termination will take effect once regulatory approval is received, meaning the prior collaboration will formally conclude only after that approval.
Amgen Inc. (AMGN) senior vice president and chief compliance officer Nancy A. Grygiel reported option exercises and related stock sales. On 11/20/2025, she exercised options to buy 1,500 shares of common stock at $177.46 per share and 1,639 shares at $162.60 per share, then sold 1,500 shares and 1,639 shares of common stock at an average price of $337.2625 per share.
After these transactions, she directly beneficially owned 7,225 shares of Amgen common stock, which include 96 dividend equivalent units tied to unvested RSUs, and also held 104.6847 shares through the company 401(k) plan’s stock fund. She continued to hold 1,970 nonqualified stock options from the 04/27/2020 grant, while the 05/01/2019 option grant was fully exercised.
Amgen (AMGN) insider transaction: The company’s SVP of Business Development reported a sale of 890 shares of Amgen common stock on 11/12/2025 (Transaction Code S) at an average price of $336.2422. The filing notes trade prices ranged from $336.2219 to $336.30 per share. Following the transaction, the reporting person beneficially owns 7,082 shares, held directly. This balance includes 93 Dividend Equivalents credited to unvested RSUs under Amgen’s equity plan.
Amgen (AMGN) insider transaction: EVP, Global Commercial Ops Murdo Gordon filed a Form 4 reporting an open‑market sale of 6,879 shares of common stock on 11/12/2025 at an average price of $336.8326.
After the trade, Gordon beneficially owns 41,923 shares. This figure includes 647 dividend equivalents (DEs) credited to unvested RSUs under Amgen’s equity plan, which pay out in shares on a one‑to‑one basis according to the vesting schedule.
Amgen (AMGN) reported insider activity by its EVP & Chief Technology Officer. On 11/11/2025, the officer made a gift of 6,490 shares of common stock, followed by a gift of 309 shares on 11/12/2025, both at $0 per share (Form 4 code G). After these transactions, the officer beneficially owned 35,503 shares.
The filing notes the first gift went to a charitable donor‑advised fund and the second to a non‑profit organization. The reported holdings include 583 dividend equivalents credited to unvested RSUs, payable in shares pursuant to the vesting schedule.
Amgen Inc. (AMGN) reported an insider transaction. Director S. Omar Ishrak acquired 218.6134 shares of Common Stock on 11/07/2025 at $0, increasing his beneficial ownership to 6,507.5436 shares, held directly.
The filing notes these holdings include 338 Dividend Equivalents credited under the Director Program, which are paid in Amgen Common Stock on a one-to-one basis, with cash for any remaining fractional share amount.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
